இருதயவியல் அறிவியல் அமர்வுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இருதயவியல் அறிவியல் அமர்வுகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இருதயவியல் அறிவியல் அமர்வுகள் Today - Breaking & Trending Today

What's the Best Aspirin Dose for Secondary Prevention of CAD?

What's the Best Aspirin Dose for Secondary Prevention of CAD?
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

American College Of Cardiology Scientific Sessions , Cardiology Scientific Sessions , அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் அறிவியல் அமர்வுகள் , இருதயவியல் அறிவியல் அமர்வுகள் ,

Prevencio Announces Laboratory Commercialization Partnership with Atlas Genomics Incorporating Microsoft's AI-computing Cloud

Press release content from Business Wire. The AP news staff was not involved in its creation.
Prevencio Announces Laboratory Commercialization Partnership with Atlas Genomics Incorporating Microsoft’s AI-computing Cloud
April 21, 2021 GMT
KIRKLAND, Wash. (BUSINESS WIRE) Apr 21, 2021
Prevencio, Inc. today announces an Agreement with Atlas Genomics to commercially launch its highly accurate, AI-driven HART blood tests for heart disease and risk of heart attack, stroke, and cardiovascular death. The HART blood tests are now available and can be ordered through your physician.
Atlas Genomics is a CLIA-certified, high complexity diagnostic lab providing the highest quality of testing, service, and technology. Prevencio’s and Atlas’ partnership incorporates the use of Microsoft’s Azure AI-computing cloud for HART algorithm processing, scoring, report generation and secure physician delivery of Prevencio’s HART test reports. Additional terms of the deal are ....

United States , Rhonda Rhyne , Christiaan Boer , Michael Kalnoski , European Society Of Cardiology Congress , Journal Of American Heart Association , Journal Of American College Cardiology , American Heart Association Scientific Sessions , American Diabetes Association Scientific Sessions , Prevencio Inc , American College Of Cardiology Scientific Sessions , Atlas Genomics , Chief Executive , Massachusetts General Hospital , Atlas Genomic , Chief Medical Officer , European Society , Cardiology Congress , American College , Cardiology Scientific Sessions , American Journal , Open Heart , Clinical Cardiology , American Heart Association , Cardiovascular Disease , Machine Learning ,

Update on DARE-19 Phase III trial for Farxiga in COVID-19

Date Time
Update on DARE-19 Phase III trial for Farxiga in COVID-19
AstraZeneca and Saint Luke’s Mid America Heart Institute today announced high-level results of the primary analysis from the DARE-19 Phase III trial assessing the potential of Farxiga (dapagliflozin) to treat patients hospitalised with COVID-19 who are at risk of developing serious complications.
The trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a change in clinical status (from early recovery to death), at 30 days.
DARE-19 was the first Phase III trial to evaluate the safety and efficacy of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients hospitalised with COVID-19 who also have risk factors for developing serious complications, including hypertension (HTN), type-2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), heart failure ( ....

United Kingdom , Mikhailn Kosiborod , Company On Twitter Astrazeneca , Research At Saint Luke Health System , Saint Luke Mid America Heart Institute , Saint Luke , Mid America Heart Institute , Vice President , Health System , Executive Vice President , American College , Cardiology Scientific Sessions , Cardiovascular Health , Clinical Trials , Kidney Disease , Heart Failure , Heart Attack , ஒன்றுபட்டது கிஂக்டம் , ஆராய்ச்சி இல் துறவி லூக் ஆரோக்கியம் அமைப்பு , துறவி லூக் நடுவில் அமெரிக்கா இதயம் நிறுவனம் , துறவி லூக் , நடுவில் அமெரிக்கா இதயம் நிறுவனம் , துணை ப்ரெஸிடெஂட் , ஆரோக்கியம் அமைப்பு , நிர்வாகி துணை ப்ரெஸிடெஂட் , அமெரிக்கன் கல்லூரி ,

AstraZeneca's Farxiga fails to meet primary goal as potential Covid-19 treatment | 12 April 2021

12 April 2021 | 07:49am
StockMarketWire.com - Pharmaceutical maker AstraZeneca and Saint Luke s Mid America Heart Institute said high-level results from a phase 3 trial assessing the potential of Farxiga to treat patients hospitalised with COVID-19 failed to meet its primary goal.
The trial failed to achieve statistical significance for the primary goal of prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a change in clinical status (from early recovery to death), at 30 days, the company said.
The full trial results would be presented at the American College of Cardiology Scientific Sessions in May 2021.
Story provided by StockMarketWire.com ....

Saint Luke Mid America Heart Institute , Saint Luke , Mid America Heart Institute , American College , Cardiology Scientific Sessions , Astrazeneca Plc , Lon Azn , Azn L , துறவி லூக் நடுவில் அமெரிக்கா இதயம் நிறுவனம் , துறவி லூக் , நடுவில் அமெரிக்கா இதயம் நிறுவனம் , அமெரிக்கன் கல்லூரி , இருதயவியல் அறிவியல் அமர்வுகள் , லோன் அஸ்ர் , அஸ்ர் ல் ,

50% of US adults expected to have at least one dose of Covid-19 vaccine by end of this week

9:51 a.m. ET, April 12, 2021
50% of US adults expected to have at least one dose of Covid-19 vaccine by end of this week
From CNN s Deidre McPhillips
People wait in line at a pop-up Coviid-19 vaccination site in Orlando, Florida, on April 9. Paul Hennessy/SOPA Images/LightRocket/Getty Images
If Covid-19 vaccinations continue at the current pace, the United States will likely hit a milestone this week: vaccinating half of adults with at least one dose of vaccine.
Over the past week, more than 3.1 million doses of vaccine have been administered each day on average, according to data reported by the US Centers for Disease Control and Prevention. Those doses could be first doses, second doses or single doses. ....

United States , Hong Kong , United Kingdom , Angela Merkel , Sophia Saifi , Anna Stewart , Dan Kitwood Getty , Asim Hafeez Bloomberg Getty , Eric Cheung , Jessie Yeung , Gavin Newsom , Los Angeles , Nicquel Terry Ellis , Deidre Mcphillips , Esha Mitra , Mukesh Thakur , Yoshihide Suga , Mikhail Kosiborod , Christian Karagiannidis , Naomi Thomas , Priya Krishnakumar , Jason Armond Los Angeles , Sanjay Gunjyal , Fred Pleitgen , Hollie Silverman , Christina Maxouris ,